Fig 1: Validation of the prognostic value of metabolism-related risk model (MRM) in two independent prostate cancer (PCa) cohorts and real-world study. (A) Kaplan–Meier analysis for disease-free survival (DFS) curves of patients in low or high metabolism-related risk score (MRS) subgroups from two independent validation cohorts (Taylor and International Cancer Genome Consortium (ICGC) PCa). (B) Receiver operating characteristic (ROC) curves for predicting 1-, 3-, and 5-year DFS in patients from Taylor and ICGC PCa cohorts. (C) ROC analysis showed that the predictive accuracy of MRM in DFS was superior to other clinical features in Taylor and ICGC PCa cohorts. (D, E) Univariate and multivariate Cox regression analyses of MRS and clinical features in Taylor and ICGC PCa cohorts. (F, G) Immunohistochemistry (IHC) staining was performed to detect the key metabolism-related differentially expressed genes (mDEGs) (AHSG, APOE, BGN, SLC2A4, and CYP2D6) protein expression using PCa tissue arrays from 59 normal tissues and 196 tumor tissues. Representative images are shown. Statistical analysis of the immunoreactive score (IRS) scores of IHC staining. *p < 0.05; **p < 0.01; ***p < 0.001.